{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:34:07Z","timestamp":1787610847646,"version":"build-2736575974"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300019C"],"award-info":[{"award-number":["HHSN272201300019C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["360G-Wellcome-101999\/Z\/13\/Z"],"award-info":[{"award-number":["360G-Wellcome-101999\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSO100201900007C"],"award-info":[{"award-number":["HHSO100201900007C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,1,24]]},"abstract":"<jats:p>\n            Taniborbactam is a novel cyclic boronate \u03b2-lactamase inhibitor in clinical development in combination with cefepime. We assessed the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of cefepime-taniborbactam and comparators against a 2018\u20132020 collection of\n            <jats:italic>Enterobacterales<\/jats:italic>\n            (\n            <jats:italic>n\u2009<\/jats:italic>\n            =\u200913,731) and\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            (\n            <jats:italic>n\u2009<\/jats:italic>\n            =\u20094,619) isolates cultured from infected patients attending hospitals in 56 countries.\n          <\/jats:p>","DOI":"10.1128\/aac.01281-22","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T14:02:14Z","timestamp":1671631334000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":72,"title":["<i>In Vitro<\/i>\n            Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program"],"prefix":"10.1128","volume":"67","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":true,"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Wise","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Six","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Uehara","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9287-2997","authenticated-orcid":true,"given":"Denis M.","family":"Daigle","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Cusick","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Pevear","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy347"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02000-20"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz571"},{"key":"e_1_3_3_6_2","unstructured":"World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"e_1_3_3_7_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa511"},{"key":"e_1_3_3_9_2","unstructured":"Clinical Trials. 2021. Safety and Efficacy Study of Cefepime\/VNRX-5133 in Patients With Complicated Urinary Tract Infections (CERTAIN-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840148."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa391"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab197"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02161-21"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106440"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106228"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa053"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0699-6"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000667"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku568"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0122"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01589-17"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013092107"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00685"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066236"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/2049-632X.12208"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01388-12"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01997-14"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03113-15"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz173"},{"key":"e_1_3_3_31_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. M07. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_32_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance standards for antimicrobial susceptibility testing, 31th ed. M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_3_33_2","unstructured":"EUCAST. 2021. Clinical breakpoints v11.0. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa373"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab405"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01053-21"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00253-22"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa345"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01069-13"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01301-09"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2015.05.005"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01281-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01281-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T14:03:14Z","timestamp":1674568994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01281-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,24]]}},"alternative-id":["10.1128\/aac.01281-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01281-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"2022-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01281-22"}}